PMID- 22410801
OWN - NLM
STAT- MEDLINE
DCOM- 20130627
LR  - 20220310
IS  - 1436-3305 (Electronic)
IS  - 1436-3291 (Linking)
VI  - 16
IP  - 1
DP  - 2013 Jan
TI  - HER2 expression and its clinicopathological features in resectable gastric 
      cancer.
PG  - 84-93
LID - 10.1007/s10120-012-0150-9 [doi]
AB  - BACKGROUND: A recent randomized controlled trial (Trastuzumab for Gastric Cancer 
      [ToGA] study) established standard scoring criteria of human epidermal growth 
      factor receptor 2 (HER2) for gastric cancer and demonstrated the efficacy of 
      trastuzumab for treating metastatic gastric cancer. The aim of the present study 
      was to evaluate the frequency of HER2-positive cases by application of the 
      standard criteria in patients with resectable gastric cancer and to examine the 
      relationships between HER2 expression and prognosis, mucin phenotype, p53 status, 
      and clinicopathological features. METHODS: A total of 213 patients were included 
      in this retrospective study. All tumor samples were examined for HER2 expression 
      by immunohistochemistry (IHC), HER2 amplification by in situ hybridization, and 
      mucin and p53 expression by staining for CD10, MUC2, MUC5AC, MUC6, and p53. 
      RESULTS: HER2-positive tumors were identified in 25 patients (11.7 %). 
      HER2-positive cases were more frequently found in men, older patients, and in the 
      intestinal histological type (P = 0.0048, 0.0309, and <0.0001, respectively). 
      Although no association was found between HER2 overexpression and mucin 
      phenotype, the expression of CD10 and p53 was significantly correlated with HER2 
      positivity (P = 0.0079 and 0.013). The overall survival of HER2-negative and 
      -positive patients was not significantly different. However, in patients with 
      stage III/IV, overall survival was worse in HER2-positive patients (P = 0.0149). 
      In a comparison between dual-color in situ hybridization (DISH) and fluorescence 
      in situ hybridization (FISH), four IHC2+/3+ cases that were DISH-positive were 
      judged as negative by FISH. CONCLUSIONS: Our study indicated that HER2 expression 
      was less frequent in resectable gastric cancer than in metastatic gastric cancer. 
      The impact of HER2 expression on survival was limited. DISH was superior to FISH 
      for evaluating cases with limited HER2 expression.
FAU - Kataoka, Yoshiki
AU  - Kataoka Y
AD  - Department of Surgery, Graduate School of Medicine, Kyoto University, 54 Shogoin 
      Kawahara-Cho, Sakyo-ku, Kyoto, 606-8507, Japan.
FAU - Okabe, Hiroshi
AU  - Okabe H
FAU - Yoshizawa, Akihiko
AU  - Yoshizawa A
FAU - Minamiguchi, Sachiko
AU  - Minamiguchi S
FAU - Yoshimura, Kenichi
AU  - Yoshimura K
FAU - Haga, Hironori
AU  - Haga H
FAU - Sakai, Yoshiharu
AU  - Sakai Y
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120314
PL  - Japan
TA  - Gastric Cancer
JT  - Gastric cancer : official journal of the International Gastric Cancer Association 
      and the Japanese Gastric Cancer Association
JID - 100886238
RN  - 0 (Tumor Suppressor Protein p53)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 3.4.24.11 (Neprilysin)
SB  - IM
MH  - Age Factors
MH  - Aged
MH  - Aged, 80 and over
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - In Situ Hybridization/*methods
MH  - In Situ Hybridization, Fluorescence/methods
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Staging
MH  - Neprilysin/genetics
MH  - Prognosis
MH  - Receptor, ErbB-2/*genetics
MH  - Retrospective Studies
MH  - Sex Factors
MH  - Stomach Neoplasms/genetics/*pathology/surgery
MH  - Survival Rate
MH  - Tumor Suppressor Protein p53/genetics
EDAT- 2012/03/14 06:00
MHDA- 2013/06/29 06:00
CRDT- 2012/03/14 06:00
PHST- 2011/10/08 00:00 [received]
PHST- 2012/02/16 00:00 [accepted]
PHST- 2012/03/14 06:00 [entrez]
PHST- 2012/03/14 06:00 [pubmed]
PHST- 2013/06/29 06:00 [medline]
AID - 10.1007/s10120-012-0150-9 [doi]
PST - ppublish
SO  - Gastric Cancer. 2013 Jan;16(1):84-93. doi: 10.1007/s10120-012-0150-9. Epub 2012 
      Mar 14.